Home Biotechnology Industry News Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter…

Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter…

Oryzon announced today that it is entering preclinical development with its second drug candidate, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of...

(PRWeb May 24, 2012)

Read the full story at http://www.prweb.com/releases/2012/5/prweb9533996.htm